Rafferty Asset Management
YMAB

Rafferty Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Rafferty Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-41,255
Closed -$323K – 1152
2024
Q4 		$323K Buy
41,255
+6,178
+18% +$75.2K ﹤0.01% 1014
2024
Q3 		$461K Buy
+35,077
New +$445K ﹤0.01% 948
2022
Q4 		– Sell
-101,824
Closed -$1.47M – 1160
2022
Q3 		$1.47M Buy
101,824
+51,228
+101% +$848K 0.02% 580
2022
Q2 		$766K Sell
50,596
-89,711
-64% -$1.05M 0.01% 720
2022
Q1 		$1.67M Buy
140,307
+63,731
+83% +$654K 0.01% 665
2021
Q4 		$1.24M Buy
76,576
+35,991
+89% +$769K 0.01% 793
2021
Q3 		$1.16M Sell
40,585
-5,120
-11% -$161K 0.01% 773
2021
Q2 		$1.54M Sell
45,705
-31,677
-41% -$1.02M 0.01% 751
2021
Q1 		$2.34M Buy
77,382
+71,969
+1,330% +$2.95M 0.02% 581
2020
Q4 		$268K Sell
5,413
-14,619
-73% -$676K ﹤0.01% 864
2020
Q3 		$769K Buy
20,032
+12,972
+184% +$516K 0.01% 617
2020
Q2 		$305K Buy
+7,060
New +$267K ﹤0.01% 823
2020
Q1 		– Sell
-16,962
Closed -$530K – 818
2019
Q4 		$530K Buy
+16,962
New +$502K 0.01% 678

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Rafferty Asset Management's YMAB Position: Q1 2025 in Review

Rafferty Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 41,255 shares — an estimated $323K sold.

Rafferty Asset Management first reported a position in YMAB in Q4 2019 and held it in 13 quarters. The position peaked at $2.34M in Q1 2021. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Rafferty Asset Management reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Rafferty Asset Management sold 41,255 Y-mAbs Therapeutics shares in Q1 2025, an estimated $323K.
  • Rafferty Asset Management first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 13 quarters.
  • Rafferty Asset Management's Y-mAbs Therapeutics position peaked at $2.34M in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Rafferty Asset Management's 13F filing for Q1 2025, filed 14 May 2025.